Accessibility Menu
 
Prelude Therapeutics logo

Prelude Therapeutics

(NASDAQ) PRLD

Current Price$4.70
Market Cap$296.11M
Since IPO (2020)-82%
5 Year-86%
1 Year+446%
1 Month+44%

Prelude Therapeutics Financials at a Glance

Market Cap

$296.11M

Revenue (TTM)

$12.14M

Net Income (TTM)

$99.50M

EPS (TTM)

$-1.35

P/E Ratio

-3.47

Dividend

$0.00

Beta (Volatility)

1.53 (High)

Price

$4.70

Volume

277.431

Open

$4.88

Previous Close

$4.70

Daily Range

$4.43 - $4.88

52-Week Range

$0.73 - $5.54

PRLD News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Prelude Therapeutics

Industry

Biotechnology

Employees

79

CEO

Krishna Vaddi, PhD

Headquarters

Wilmington, DE 19803, US

PRLD Financials

Key Financial Metrics (TTM)

Gross Margin

93%

Operating Margin

-9%

Net Income Margin

-8%

Return on Equity

-99%

Return on Capital

-1%

Return on Assets

-70%

Earnings Yield

-28.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$296.11M

Shares Outstanding

63.00M

Volume

277.431

Short Interest

0.00%

Avg. Volume

335.12K

Financials (TTM)

Gross Profit

$10.43M

Operating Income

$104.57M

EBITDA

$102.86M

Operating Cash Flow

$56.30M

Capital Expenditure

$67.00K

Free Cash Flow

$56.37M

Cash & ST Invst.

$103.21M

Total Debt

$17.79M

Prelude Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$5.64M

+41.0%

Gross Profit

$5.22M

+30.6%

Gross Margin

92.59%

N/A

Market Cap

$296.11M

N/A

Market Cap/Employee

$2.26M

N/A

Employees

131

N/A

Net Income

$16.46M

+42.7%

EBITDA

$16.93M

+49.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$85.42M

-26.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$15.04M

-1.8%

Short Term Debt

$2.74M

+1.6%

Return on Assets

-70.41%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

$23.12M

+211.2%

Operating Cash Flow

$23.12M

+211.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTAEnanta Pharmaceuticals, Inc.
$13.31-0.30%
FHTXFoghorn Therapeutics Inc.
$5.31+2.31%
IVAInventiva S.A.
$5.15-1.15%
OBIOOrchestra BioMed Holdings, Inc.
$4.13-0.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$82.54+0.24%
POETPoet Technologies
$15.10+0.29%
NOKNokia
$10.46+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$62.56+0.06%

Questions About PRLD

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.